First Horizon Advisors’s Verona Pharma VRNA Stock Holding History

First Horizon Advisors’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$108K	Buy	+1,141	New	+$84.5K	﹤0.01%	691

Other funds holding VRNA

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

First Horizon Advisors's VRNA Position: Q2 2025 in Review

First Horizon Advisors opened a new position in Verona Pharma (VRNA) in Q2 2025: 1,141 shares worth $108K. The stake represents ﹤0.01% of the portfolio and ranks #691 among its holdings.

292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

First Horizon Advisors held 1,141 shares of Verona Pharma worth $108K as of Q2 2025.
Verona Pharma was a new First Horizon Advisors position in Q2 2025.
Verona Pharma made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #691 holding.
292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.